迈瑞医疗 reported revenue of ¥17.75B for the period ended 2026-06-30, +6.0% year on year. Net income was ¥5.05B, a 28.4% net margin on a 60.8% gross margin. The largest revenue line is 体外诊断类产品 at 39% of the total. Free cash flow for the period was ¥3.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥17.75B | +6.0% |
| Gross profit | ¥10.80B | — |
| Operating income | ¥5.57B | — |
| Net income | ¥5.05B | -3.6% |
| Gross margin | 60.8% | Net margin 28.4% |
| Revenue Q/Q | +12.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 体外诊断类产品 | ¥6.86B | 38.7% |
| 生命信息与支持类产品 | ¥4.81B | 27.1% |
| 新兴业务类产品 | ¥3.11B | 17.5% |
| 医学影像类产品 | ¥2.84B | 16.0% |
| 其他(补充) | ¥0.13B | 0.7% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥6.95B | 39.2% |
| R&D | ¥1.57B | 8.8% |
| SG&A | ¥3.21B | 18.1% |
| Tax & other | ¥0.52B | 2.9% |
| Item | Amount |
|---|---|
| Total assets | ¥60.79B |
| Total liabilities | ¥15.48B |
| Shareholders' equity | ¥45.30B |
| Equity / assets | 74.5% |
| Operating cash flow | ¥3.50B |
| Capital expenditure | ¥0.46B |
| Free cash flow | ¥3.03B |
| Cash conversion (OCF / net income) | 97% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
指南针 ・ 新产业 ・ 安克创新 ・ 爱美客 ・ 金龙鱼 ・ 锐捷网络 ・ 软通动力 ・ 华大九天 ・ 江波龙 ・ 中航成飞 ・ 浦发银行 ・ 上海机场
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies